We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

World's First Paper-Based COVID-19 Test Could Be Game-Changer for Coronavirus Testing

By LabMedica International staff writers
Posted on 15 Oct 2020
Print article
Illustration
Illustration
An inexpensive paper-based COVID-19 test that could give fast results similar to a pregnancy test can become a game-changer for coronavirus testing.

Researchers at the CSIR-Institute of Genomics and Integrative Biology (IGIB New Delhi, India) have developed the world's first paper-based COVID-19 test that uses cutting-edge CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology for detection of genomic sequence of the novel coronavirus. The technology was conceived and developed under a sickle cell mission and utilizes an indigenously developed cutting-edge CRISPR-Cas9 technology to specifically recognize COVID-19 sequence in a sample. A combination of CRISPR biology and paper-strip chemistry leads to a visible signal readout on a paper strip that can be rapidly assessed for establishing the presence of the viral infection in a sample. The test, named Feluda - an acronym for FNCAS9 Editor-Limited Uniform Detection Assay - after a famous Indian fictional detective, would return results in under an hour and cost less than USD 7.

Feluda is expected to address the urgent need for accurate mass testing because of its affordability, relative ease of use and non-dependency on expensive qPCR (quantitative polymerase chain reaction) machines. Feluda is being brought out of the lab and made available for wide use by a leading Indian conglomerate, Tata Sons, which has signed an MoU with CSIRIGIB to license the know-how. The MoU with Tata Sons allows for scaling up this knowhow in the form of a kit that can be deployed for testing on ground.

“This innovative ‘Feluda’ test uses cutting-edge CRISPR technology for detection of genomic sequence of the novel coronavirus. It uses a test protocol that is simple to administer and easy to interpret, enabling results to be made available to the medical fraternity in relatively lesser time as compared to other test protocols,” said Banmali Agrawala, president, Infrastructure and Defence and Aerospace, Tata Sons. “We believe that CRISPR is futuristic technology that can also be configured for detection of multiple other pathogens in the future.”

Related Links:
CSIR-Institute of Genomics and Integrative Biology (IGIB)

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
SARS-CoV-2 Test
One Step SARS-CoV-2 Nucleic Acid Detection Kit (P761H)

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A massive study has identified new biomarkers for renal cancer subtypes, improving diagnosis and treatment (Photo courtesy of Jessica Johnson)

Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes

Renal cell carcinomas (RCCs) are notably diverse, encompassing over 20 distinct subtypes and generally categorized into clear cell and non-clear cell types; around 20% of all RCCs fall into the non-clear... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more